Medical Devices Park of Hyd UoH startup ties up with US unit for cancer diagnostics

Eliciton Innovation Pvt Ltd, a startup incubated at ASPIRE BioNEST of the University of Hyderabad (UoH) has tied up with Vivi Biologics, a US-based company to develop a low-cost cancer diagnostic kit to detect breast cancer on Thursday.
The collaboration between Eliciton Innovation and Vivi Biologics was formalised through an MoU, emphasising their joint mission to develop early cancer detection technologies that are both cost-effective and accessible. The primary goal of their partnership is to create novel diagnostic tools that can detect cancer at its earliest stages, facilitating timely and effective intervention.
The startup has already specialised in producing microbial-based nutritional supplements with enhanced health benefits beyond basic nutrition. It has also expanded its portfolio of human and animal diagnostics and plans to establish a diagnostic manufacturing facility at Medical Devices Park of Hyderabad. In a strategic move to advance this new venture, the company has partnered with the US-based Vivi Biologics, founded by Dr Kiran Velpula, an acclaimed cancer researcher and a member of Peoria City Council, to validate early cancer diagnostics. Dr Velpula is an alumnus of University of Hyderabad from School of Life Sciences,  a professor at the University of Illinois College of Medicine in Peoria and head of the Velpula Neuro-Oncology Lab. He is pioneering in cancer research focusing on new treatments and early diagnostic tools.
A new entity named VIVIGEN Bio Labs has been established and incubated at ASPIRE-Bio NEST.
This collaborative effort aims to democratise cancer diagnostics and significantly improve global health outcomes in oncology through innovative solutions.